Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $67.00.

A number of brokerages have recently issued reports on NTLA. Wedbush reaffirmed a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, April 23rd. Canaccord Genuity Group lifted their target price on Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Finally, Wolfe Research started coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating on the stock.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $32.99, for a total transaction of $75,778.03. Following the sale, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC lifted its holdings in Intellia Therapeutics by 14.7% during the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after buying an additional 1,463,820 shares during the last quarter. Rhenman & Partners Asset Management AB increased its stake in Intellia Therapeutics by 1,600.0% in the third quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company’s stock valued at $26,877,000 after purchasing an additional 800,000 shares during the last quarter. Norges Bank acquired a new stake in Intellia Therapeutics during the fourth quarter worth approximately $16,348,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $9,086,000. Finally, Vestmark Advisory Solutions Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $8,110,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Up 1.4 %

Shares of NASDAQ:NTLA opened at $23.60 on Tuesday. Intellia Therapeutics has a 52-week low of $19.37 and a 52-week high of $47.48. The stock has a market cap of $2.28 billion, a P/E ratio of -4.36 and a beta of 1.85. The business has a fifty day moving average of $26.06 and a two-hundred day moving average of $27.30.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. The firm had revenue of ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. During the same quarter in the prior year, the firm posted ($1.40) earnings per share. On average, equities analysts anticipate that Intellia Therapeutics will post -5.57 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.